Billionaire Profile
Hyuntae Kim
Global Rank
#3086

Image: Kim, Hyun-tae | CC BY 4.0 | via Wikimedia Commons

Hyuntae Kim

CEO, Biotech
SOUTH KOREA
Real-Time Net Worth
$1.187B
Estimated based on Biotech stock value as of May 3, 2026
0% (24h)
Age
50
Source
Biotech
Industry
Healthcare
Citizenship
SOUTH KOREA

Biography

Hyuntae Kim, the CEO of Voronoi, a South Korean biotechnology company, is a self-made billionaire with a net worth of $1.2 Billion as of March 23, 2026. He earned a Bachelor of Business Administration and a Master of Business Administration from Seoul National University. Kim took over Voronoi in 2016 after it was founded by his younger brother, Hyun-seok, and listed it on Korea's Kosdaq in 2022. Before Voronoi, Kim held leadership positions in asset management at eBest Investment & Securities, Hanwha Investment & Securities, and KB Securities. Kim's leadership has been instrumental in Voronoi's development of promising cancer drug candidates. He is married and resides in Incheon, South Korea.

Fact Checked
Verified by Editorial Team
Live Data
Updated 5/3/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Hyuntae Kim, the current CEO of Voronoi, embarked on his entrepreneurial journey after a successful career in the financial sector. Kim earned both his Bachelor of Business Administration and his Master of Business Administration from Seoul National University.

Rise to Success

Kim's career began in the financial sector, where he held significant positions in asset management. Prior to leading Voronoi, Kim held key roles at eBest Investment & Securities, Hanwha Investment & Securities, and KB Securities. In 2016, Kim took over the leadership of Voronoi, a biotechnology company founded by his younger brother in 2015. Voronoi was listed on Korea's Kosdaq stock exchange in 2022, which marked a significant milestone.

Key Business Strategies

Under Kim's leadership, Voronoi has focused on developing innovative cancer drug candidates, with VRN10 and VRN11 being the most promising. The company's strategy includes leveraging an AI platform, Voronomics, to accelerate drug development. Kim's strategic vision has driven Voronoi's expansion and success in the biotech industry.

Philanthropy

There is no information available about Hyuntae Kim's specific philanthropic activities.

Career Milestones

2016

CEO of Voronoi

Took over the leadership of Voronoi, a biotechnology company.

2022

Voronoi Listed on Kosdaq

Successfully listed Voronoi on the Korea's Kosdaq stock exchange.

2025

Phase 1 Clinical Trials

Voronoi's cancer drug candidates VRN10 and VRN11 started Phase 1 clinical trials.

Philanthropy & Social Impact

Category

REAL initiative

$XB

REAL description

Business Philosophy & Leadership

Notable Quotes

"REAL quote"

Leadership Principles

REAL principle

REAL description

Controversies & Challenges

YEAR

REAL controversy

REAL description